PMID- 34402201
OWN - NLM
STAT- MEDLINE
DCOM- 20220303
LR  - 20220303
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 10
IP  - 17
DP  - 2021 Sep
TI  - Front-line treatment patterns in multiple myeloma: An analysis of U.S.-based 
      electronic health records from 2011 to 2019.
PG  - 5866-5877
LID - 10.1002/cam4.4137 [doi]
AB  - Multiple myeloma (MM) treatment options have evolved rapidly, but how new agents 
      are incorporated into treatment decisions in current practice is not well 
      understood. This study examined prescribing trends of physicians treating newly 
      diagnosed MM and treatment outcomes in the United States. Electronic health 
      record data from 6271 adult patients diagnosed with MM and receiving initial 
      treatment between 1 January 2011 and 31 January 2020 were derived from the 
      Flatiron Health electronic-health record de-identified database. The number/types 
      of agents included in therapy regimens, time to next treatment (TTNT), and 
      overall survival (OS) were assessed. Subgroups were analyzed by the International 
      Staging System (ISS) disease stage at diagnosis, stem cell transplant eligibility 
      and timing, and practice type. Exploratory prognostic models evaluated the 
      association between baseline covariates and time-to-event outcomes. The 
      proportion of patients receiving triplet therapies increased from 2011 (36%) to 
      2019 (72%) as those receiving initial monotherapy or doublet therapy decreased. 
      Overall, the most prevalent triplet regimen consisted of an immunomodulatory drug 
      (IMiD), a proteasome inhibitor, and a steroid. From 2017 to 2019, median TTNT 
      from front-line to second-line was longer in patients with ISS stage I versus 
      stages II/III, and in those receiving IMiD-containing doublet or triplet 
      therapies versus other combinations. Overall median OS was 56 months and 
      increased from 2011 to 2014, after which median OS was not yet reached. Age, ISS 
      stage, and high-risk status were prognostic for both OS and TTNT, while sex, 
      practice type, and ECOG status were prognostic for OS only.
CI  - (c) 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Kumar, Shaji
AU  - Kumar S
AUID- ORCID: 0000-0001-5392-9284
AD  - Division of Hematology, Mayo Clinic, Rochester, MN, USA.
FAU - Williamson, Mellissa
AU  - Williamson M
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Ogbu, Uzor
AU  - Ogbu U
AD  - Genentech, Inc., South San Francisco, CA, USA.
FAU - Surinach, Andy
AU  - Surinach A
AD  - Genesis Research, Hoboken, NJ, USA.
FAU - Arndorfer, Stella
AU  - Arndorfer S
AD  - Genesis Research, Hoboken, NJ, USA.
FAU - Hong, Wan-Jen
AU  - Hong WJ
AD  - Genentech, Inc., South San Francisco, CA, USA.
LA  - eng
GR  - This study was funded by F. Hoffmann-La Roche, Ltd./
PT  - Historical Article
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210816
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
SB  - IM
MH  - Aged
MH  - Electronic Health Records/*standards
MH  - Female
MH  - History, 21st Century
MH  - Humans
MH  - Male
MH  - Multiple Myeloma/mortality/*therapy
MH  - Retrospective Studies
MH  - Survival Analysis
MH  - Treatment Outcome
MH  - United States
PMC - PMC8419764
OTO - NOTNLM
OT  - multiple myeloma
OT  - prescribing trends
OT  - treatment outcome
COIS- S.K. has participated in advisory boards and Independent review committees for 
      Takeda, Celgene, Janssen, Roche, AbbVie, Merck, Sanofi, and KITE (no personal 
      compensation) and has received research support from the institution for clinical 
      trials from Takeda, Celgene, Janssen, Roche, AbbVie, Merck, Sanofi, KITE, and 
      Bristol-Myers Squibb. M.W., U.O., and W.-J.H. are employees of Genentech, a 
      member of the Roche Group. A.S. and S.A. are employees of Genesis Research.
EDAT- 2021/08/18 06:00
MHDA- 2022/03/04 06:00
PMCR- 2021/08/16
CRDT- 2021/08/17 07:55
PHST- 2021/05/27 00:00 [revised]
PHST- 2021/04/27 00:00 [received]
PHST- 2021/07/01 00:00 [accepted]
PHST- 2021/08/18 06:00 [pubmed]
PHST- 2022/03/04 06:00 [medline]
PHST- 2021/08/17 07:55 [entrez]
PHST- 2021/08/16 00:00 [pmc-release]
AID - CAM44137 [pii]
AID - 10.1002/cam4.4137 [doi]
PST - ppublish
SO  - Cancer Med. 2021 Sep;10(17):5866-5877. doi: 10.1002/cam4.4137. Epub 2021 Aug 16.